Learning how to add peptide therapy to your practice means more than a supplier and a price list. This guide covers the ROI, compliance, and setup that make it sustainable.
How to add peptide therapy to your practice is a question fulfillment vendors answer with a supplier list and a price sheet. That’s not the same as building a program that lasts. A peptide offering built on judgment — clinical evaluation, compliant sourcing, honest marketing, documented consent — generates revenue and holds up to scrutiny. One built on product alone doesn’t, and the difference shows up the first time a patient has an adverse event, a state board asks a question, or the FTC reviews a testimonial. This guide covers the workflow, the economics, the compliance setup, and the competence gap that separates a durable peptide program from a supplier relationship with a landing page attached.
In This Article
Clinical Foundations
A sustainable peptide program needs systems for evaluation, informed consent, documentation, monitoring, adverse-event management, regulatory compliance, and expectation management — not just a product and a prescription pad. Start with a standardized, reproducible clinical process: a structured initial consultation covering chief complaint, medical history, current medications, and patient goals and expectations, followed by physical examination, risk stratification, relevant labs, contraindication screening, and a discussion of alternatives. From there, shared decision-making and documented informed consent close the loop before treatment begins.
Three systems sit underneath that workflow and need to exist before the first patient, not get built reactively after something goes wrong. Consent should be standardized per peptide class and kept current with regulatory status, not treated as a generic form. Adverse-event management needs written patient instructions, a documentation process, and a MedWatch reporting habit for compounded products, since they don’t have the post-market surveillance that approved drugs do. And because peptide patients tend to be older and on other medications, screen for drug-drug interactions as a matter of routine — GLP-1s slowing gastric emptying can affect absorption of other oral drugs, growth hormone secretagogues can interact with glucose medications, and immunomodulatory peptides carry theoretical interactions with immunosuppressants.
Standardized Consent
Standardize consent per peptide class and keep it current with regulatory status; do not treat it as a generic form.
Adverse-Event Management
Use written patient instructions, a documentation process, and a MedWatch reporting habit for compounded products.
Interaction Screening
Screen for drug-drug interactions as a matter of routine, including glucose medications and oral-drug absorption considerations.
Practice Economics
Most peptide therapy programs operate outside insurance reimbursement, and cash-pay or concierge is the dominant model. Initial consultation fees commonly range from $200 to $500 or more, reflecting the depth of evaluation involved. Monthly program fees, covering protocol management, follow-up, lab review, and dose adjustments, commonly run $150 to $400. Labs — CBC, CMP, IGF-1, HbA1c, depending on the protocol — are typically billed separately, and compounded medication costs should pass through to the patient without an undisclosed markup. Transparent, itemized pricing isn’t just good practice; it’s what keeps a cash-pay model defensible if it’s ever questioned.
| Program Component | Typical Pricing | Disclosure Standard |
|---|---|---|
| Initial Consultation | $200–$500+ | Reflect the depth of evaluation involved. |
| Monthly Program Fee | $150–$400 | Cover protocol management, follow-up, lab review, and dose adjustments. |
| Labs | Billed separately | Disclose separately; CBC, CMP, IGF-1, HbA1c depend on the protocol. |
| Compounded Medication | Pass-through | Pass through to the patient without an undisclosed markup. |
Initial Consultation
$200–$500+
Reflect the depth of evaluation involved.
Monthly Program Fee
$150–$400
Protocol management, follow-up, lab review, and dose adjustments.
Labs
Billed separately
Disclose separately; testing depends on the protocol.
Compounded Medication
Pass-through
No undisclosed markup.
Pricing structure only holds up if the clinical judgment behind it does too. Building both together — the economics and the evaluation standard that justifies them — is part of what the IAPAM peptide therapy course is designed to teach.
Vendor Due Diligence
Sourcing is one of the most consequential decisions in setting up a peptide program. 503A pharmacies compound patient-specific prescriptions; before using one, verify active state licensure, which bulk substances they’re permitted to compound, and request a lot number and certificate of analysis. 503B outsourcing facilities operate under cGMP and can supply without a patient-specific prescription, but only from the bulks list or during an active shortage — and that matters directly for GLP-1s, since semaglutide and tirzepatide are both off the shortage list, with their exclusion from the 503B bulks list currently proposed. If that exclusion is finalized, compounded GLP-1 sourced from a 503B facility outside the bulks list would no longer be a legal option; verify current status before building a program around it.
Research-use-only and gray-market sourcing should be rejected outright, not weighed as a cost tradeoff. Red flags include “research use only” labeling, no-prescription sales, prices well below normal compounding rates, and missing licensure, lot numbers, or certificates of analysis. Providers who source from these channels face state medical board action, prescribing liability, and DEA or FDA enforcement exposure — a risk that isn’t offset by a lower per-vial cost.
503A Pharmacy
Patient-specific compounding. Verify active state licensure, permitted bulk substances, lot number, and certificate of analysis.
503B Outsourcing Facility
Operates under cGMP and can supply without a patient-specific prescription, subject to bulks-list or active-shortage limits.
Reject Outright
Research-use-only labeling, no-prescription sales, prices well below normal compounding rates, or missing licensure, lot numbers, or certificates of analysis.
Getting sourcing decisions right consistently, not just on the first vendor you evaluate, is exactly the kind of judgment the IAPAM peptide therapy course trains providers to apply before they’re standing in front of a compliance question with a patient waiting.
Marketing Compliance
Marketing is where a lot of peptide programs create legal exposure without realizing it. Claims that an unapproved compounded peptide treats, cures, or prevents a condition — “BPC-157 heals tendons,” “CJC-1295 burns fat” — can constitute promotional labeling for an unapproved drug, which is FDA territory, not just an aggressive ad. Consult counsel before finalizing marketing language for any compounded or investigational peptide.
The FTC adds a second layer: testimonials must reflect typical results, material connections need disclosure, and health claims require competent, reliable scientific substantiation. Compliant marketing leans on the provider’s credentials, clinical process, and evidence-based evaluation rather than efficacy promises for products that haven’t earned them. That’s a more defensible pitch anyway — it’s the judgment a patient is actually paying for.
Avoid
Disease-treatment, cure, prevention, or efficacy claims for unapproved compounded peptides; testimonials that do not reflect typical results; undisclosed material connections.
Lead With
Provider credentials, clinical process, evidence-based evaluation, and claims supported by competent, reliable scientific substantiation.
Team Readiness
Many patients arrive with expectations shaped by influencer content that exceeds what the evidence supports. Managing that gap is a competence problem, not a fulfillment problem — it requires trained clinical judgment to counsel a patient accurately without either dismissing their interest or overpromising results the peptide can’t deliver. That’s the piece a supplier relationship alone can’t provide, and it’s the reason a program built on judgment outperforms one built on product access over the long run. Train the team on this before launch, not during the first difficult conversation.
Key Takeaways
A sustainable peptide program needs systems — evaluation, consent, documentation, monitoring, adverse-event management — not just a supplier relationship.
Cash-pay economics work when pricing is transparent: consult fees of $200–$500+, monthly program fees of $150–$400, labs and compounded medication costs disclosed and passed through without markup.
Sourcing must be 503A or 503B compliant, with licensure, lot numbers, and certificates of analysis verified — reject RUO and gray-market sourcing outright, and verify the GLP-1 503B bulks-list status before relying on it.
Marketing should avoid efficacy or cure claims for unapproved peptides and lean on credentials and process instead, with testimonials substantiated per FTC requirements.
Standardized consent and adverse-event reporting processes protect patients and the practice — build them before launch, not after an incident.
Train the team first. Getting the clinical workflow, sourcing judgment, and compliant marketing right from day one is what the IAPAM peptide therapy course is built to teach, and it’s the difference between a program that lasts and one that’s one bad review or one board inquiry away from unwinding. If you haven’t evaluated a certification yet, our guide to peptide therapy certification covers what to look for before you commit. For the broader picture, see our peptide therapy for providers hub.
Frequently Asked Questions
It can be, when priced transparently. Initial consultations commonly run $200 to $500 or more, and monthly program fees commonly run $150 to $400, with labs and compounded medication costs disclosed and billed separately rather than folded into an undisclosed markup.
No. Most peptide therapy programs operate outside insurance reimbursement on a cash-pay or concierge basis, which is the dominant model in this category.
Through a properly licensed 503A pharmacy (patient-specific compounding, verified state licensure, lot number, certificate of analysis) or a 503B outsourcing facility operating within the bulks list or an active shortage. Reject research-use-only or gray-market sources entirely — no exceptions for price.
Avoid disease-treatment or cure claims for unapproved compounded peptides, since those can constitute promotional labeling for an unapproved drug. Ensure testimonials reflect typical results with proper disclosure, and lean marketing on credentials and clinical process rather than efficacy promises.
Standardized, peptide-class-specific informed consent kept current with regulatory status, retained in the medical record, plus a documented process for adverse-event management and MedWatch reporting for compounded products.
Train the team on expectation management before the first patient walks in. Many patients arrive with influencer-shaped expectations that exceed the evidence, and managing that gap accurately requires clinical judgment the team needs to have in place from day one, not develop reactively.
Build the Program, Not a Workaround
Build the clinical workflow, sourcing judgment, and compliant marketing foundation before launch.
Peptide Therapy Course
Clinical workflow, regulatory context, sourcing, consent, and compliant practice integration.
Explore the Course →Peptide Therapy Certification
Compare what a rigorous certification should cover before you commit.
Compare Certifications →Peptide Therapy Hub
The complete clinical guide to FDA status, evidence, sourcing, and practice integration.
Back to Hub →Terms and conditions apply. Offer expires September 30.